Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

MHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immuno-Oncology Conference

SMi Group
Posted on: 11 Sep 18
MHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immuno-Oncology Conference

SMi Reports: Industry leaders MHRA, Pfizer, Autolus, Tusk Therapeutics, KCL, Boehringer Ingelheim and more are amongst the latest organisations to register for Immuno-Oncology 2018 (


There’s just 2 weeks until SMi’s Immuno-Oncology conference commences in London on the 26th and 27th September. With limited places left, interested attendees are urged to book soon to avoid missing out on joining an international gathering of immuno-therapy experts at this highly-anticipated conference.


Recent Confirmed Attendees Include:


  • Autolus
  • Glenmark Pharmaceuticals Ltd
  • Boehringer Ingelheim
  • National Cancer Institute
  • ImmuneBiotech AB
  • Tusk Therapeutics
  • Kings College London
  • Inserm
  • Pfizer
  • Gunma University
  • Cancer Research UK
  • Parker Institute for Cancer Immunotherapy
  • And many more!


Attendees will have the opportunity to hear from an exceptional speaker line-up giving key updates on durable cancer therapies, exclusive trial updates, and recent advances in the ever-evolving field of Immuno-Oncology.


A new generation of promising cancer therapies could dramatically extend survival rates of cancer patients, with new immuno-therapy agents constantly in development making unparalleled advances in the field.


This year's Immuno-Oncology conference aims to explore the latest developments in immuno-therapy, with a particular focus on the latest cancer treatments including Keytruda, targeting immune checkpoints, CAR T-Cell therapy, bispecific antibodies, and combination treatments.


The two-day conference will also be welcoming Shahram Lavasani, the CEO of ImmuneBiotech AB, who will be presenting at the end of day one on “Could the Microbiome Boost Cancer Immunotherapy?” Shahram holds a PhD degree from Lund University in Medical Inflammation Research, where he studied the immunoregulation and novel immunotherapies in multiple sclerosis. He is a skilful immunologist with many years of research expertise on gastrointestinal complications in chronic inflammatory diseases.


He is the founder of ImmuneBiotech, developed a proprietary lactobacilli library, and established careful and multiple selection methods to screen and design formulations for the optimal therapeutic management of the diseases. Shahram’s presentation will be focusing on the dynamics and function of the human microbiome in health and disease, dysbiosis and cancer therapy, and microbial interventions.


Visit the website to download the latest brochure, full speaker line-up and other exclusive content. Register your place at:


---- END ----

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

For more information:

Editor's Details

Maria Mandic
SMi Group

Last updated on: 11/09/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.